The Cytokinetics, Incorporated (NASDAQ:CYTK) Analysts Have Been Trimming Their Sales Forecasts

Today is shaping up negative for Cytokinetics, Incorporated (NASDAQ:CYTK) shareholders, with the analysts delivering a substantial negative revision to this year's forecasts. This report focused on revenue estimates, and it looks as though the consensus view of the business has become substantially more conservative.

We've discovered 3 warning signs about Cytokinetics. View them for free.

Following the downgrade, the most recent consensus for Cytokinetics from its 19 analysts is for revenues of US$24m in 2025 which, if met, would be a huge 23% increase on its sales over the past 12 months. Before the latest update, the analysts were foreseeing US$32m of revenue in 2025. It looks like forecasts have become a fair bit less optimistic on Cytokinetics, given the pretty serious reduction to revenue estimates.

See our latest analysis for Cytokinetics

Another way we can view these estimates is in the context of the bigger picture, such as how the forecasts stack up against past performance, and whether forecasts are more or less bullish relative to other companies in the industry. For example, we noticed that Cytokinetics' rate of growth is expected to accelerate meaningfully, with revenues forecast to exhibit 31% growth to the end of 2025 on an annualised basis. That is well above its historical decline of 18% a year over the past five years. By contrast, our data suggests that other companies (with analyst coverage) in the industry are forecast to see their revenue grow 17% per year. Not only are Cytokinetics' revenues expected to improve, it seems that the analysts are also expecting it to grow faster than the wider industry.

The Bottom Line

The most important thing to take away is that analysts cut their revenue estimates for this year. Analysts also expect revenues to grow faster than the wider market. Overall, given the drastic downgrade to this year's forecasts, we'd be feeling a little more wary of Cytokinetics going forwards.

As you can see, the analysts clearly aren't bullish, and there might be good reason for that. We've identified some potential issues with Cytokinetics' financials, such as recent substantial insider selling. For more information, you can click here to discover this and the 2 other flags we've identified.

Of course, seeing company management invest large sums of money in a stock can be just as useful as knowing whether analysts are downgrading their estimates. So you may also wish to search this free list of stocks with high insider ownership.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.